X4 Pharmaceuticals (XFOR) Receivables (2019 - 2026)

X4 Pharmaceuticals (XFOR) has reported Receivables for 6 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 9.76% year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.0 million (up 9.76% YoY), and the FY2025 full-year result was $573000.0, down 66.49% from the prior year.
• Receivables climbed to $2.0 million in Q2 2026 per XFOR's latest filing, from $1.1 million in the prior quarter.
• Across five years, Receivables topped out at $2.0 million in Q2 2026 and bottomed at $562000.0 in Q4 2023.
• Historically, Receivables has averaged $1.3 million across 4 years, with a median of $1.1 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Receivables surged 204.27% in 2024, then slumped 66.49% in 2025.
• Over 4 years, Receivables stood at $562000.0 in 2023, then soared by 204.27% to $1.7 million in 2024, then slumped by 66.49% to $573000.0 in 2025, then surged by 257.24% to $2.0 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $2.0 million, $1.1 million, and $573000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.